NDAORALSOLUTION
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
EPANED (enalapril maleate) by R-Pharm US is enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPANED is an oral solution formulation of enalapril maleate, an ACE inhibitor approved in 2016 for hypertension treatment. The drug works by inhibiting angiotensin-converting enzyme, which suppresses the renin-angiotensin-aldosterone system and reduces vasoconstriction. It is indicated as monotherapy or in combination with other antihypertensives for blood pressure management.
$0.16MPart D
Peak9.9 years to LOEThe product is in peak lifecycle phase with minimal Part D claims (131 in 2023), indicating a niche or emerging market position with limited commercial momentum.
Mechanism of Action
Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion…
Indications (1)
Worked on EPANED at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.